Abstract: A system may include a therapy device configured to deliver a therapy to a patient, a feature detector, and a feature selection controller. The therapy device may include sensing circuitry configured to sense a biological signal from the patient, and a closed-loop controller operably connected to the therapy device and the sensing circuitry. The controller may be configured to implement a feedback control algorithm to control the delivered therapy based on the sensed signal by controlling at least one therapy parameter. The feature detector may be configured to detect a plurality of available features of the biological signal. The feature selection controller may be configured to implement a feature selection algorithm to determine closed-loop sensed feature(s) from the plurality of available features. The feedback control algorithm may be configured to use the at least one closed-loop sensed feature to control the therapy parameter(s).

Abstract: Devices, systems and methods for applying electromagnetic fields to liquids, such as water, to treat unwanted material in the liquid are disclosed. Such devices, systems and methods may include a cylindrically shaped, water-immersible probe configured to generate electromagnetic fields that are effective to treat unwanted materials, such as scale, and microbes in the water.

Abstract: Electromagnetic water treatment devices for applying electromagnetic fields to liquids, such as water are disclosed. The water treatment devices may include a water-immersible probe configured to generate electromagnetic output fields effective to remove scale, prevent the growth of scale and/or eliminate microbes in a water supply system. Systems and methods for treating water using the disclosed devices are also provided.

Abstract: Devices, systems and methods for applying electromagnetic fields to liquids, such as water, to treat unwanted material in the liquid are disclosed. Such devices, systems and methods may include a cylindrically shaped, water-immersible probe configured to generate electromagnetic fields that are effective to treat unwanted materials, such as scale, and microbes in the water.

Abstract: Electromagnetic water treatment devices for applying electromagnetic fields to liquids, such as water are disclosed. The water treatment devices may include a water-immersible probe configured to generate electromagnetic output fields effective to remove scale, prevent the growth of scale and/or eliminate microbes in a water supply system. Systems and methods for treating water using the disclosed devices are also provided.

Abstract: The present invention relates to a radiation sensitive liposome, and the use of this liposome as carrier for therapeutic and diagnostic agent(s). In particular, the invention encompasses a liposomal delivery system, comprising a stable liposome-forming lipid and a polymerizable colipid, a fraction of which polymerizable colipid polymerizes upon exposure to ionizing radiation, thereby destabilizing the liposomal membrane. Destabilization of liposomes allows for leakage of liposomal contents. The present invention further contemplates methods of diagnosing and treating conditions and diseases that are responsive to liposome-encapsulated or associated agents.

Abstract: A method of solid phase selection of peptide ligands for target proteins is presented. 15-20mers or greater are addressed in a microarray, and the target protein and optional competitor bound thereto and binding compared. A specific signal for the target protein indicates that a peptide has strong affinity for the target. Ligands can be coupled to solid supports and used for affinity purification of the target proteins as well as detection and modulation of target proteins. Specific peptide ligands for immuno-purifying norovirus.

Abstract: The invention relates to the finding that T cell protein tyrosine phosphatase (TCPTP) has a tumour suppressor function. In one particular application, the invention provides a method of diagnosis and/or prognosis of cancer in a subject involving the assessment, in a suitable body sample, of any lack or reduction of TCPTP protein and/or Ptpn2 gene expression. The invention also provides a method of treating or preventing cancer in a subject involving administering to a subject an agent for modulating the activity of TCPTP.

Abstract: The present invention relates to a radiation sensitive liposome, and the use of this liposome as carrier for therapeutic and diagnostic agent(s). In particular, the invention encompasses a liposomal delivery system, comprising a stable liposome-forming lipid and a polymerizable colipid, a fraction of which polymerizable colipid polymerizes upon exposure to ionizing radiation, thereby destabilizing the liposomal membrane. Destabilization of liposomes allows for leakage of liposomal contents. The present invention further contemplates methods of diagnosing and treating conditions and diseases that are responsive to liposome-encapsulated or associated agents.

Abstract: The present invention relates to a radiation sensitive liposome, and the use of this liposome as carrier for therapeutic and diagnostic agent(s). In particular, the invention encompasses a liposomal delivery system, comprising a stable liposome-forming lipid and a polymerizable colipid, a fraction of which polymerizable colipid polymerizes upon exposure to ionizing, radiation, thereby destabilizing the liposomal membrane. Destabilization of liposomes allows for leakage of liposomal contents. The present invention further contemplates methods of diagnosing and treating conditions and diseases that are responsive to liposome-encapsulated or associated agents.

Abstract: The invention is a CD109 nucleic acid molecule and its corresponding polypeptide. The invention also includes biologically functional equivalent nucleic acid molecules and polypeptides. The invention also relates to methods of using these nucleic acid sequences and polypeptides in medical diagnosis and treatment and in drug screening.

Abstract: A method of imaging a patient's uncompressed region of interest using X-ray cone beam computed tomography or cone beam digital tomography comprises the step of introducing an effective amount of a contrast agent to the uncompressed region of interest. A system for imaging a patient's uncompressed region of interest using cone beam computed tomography (CBCT) or cone beam digital tomography (CBDT) comprises an X-ray source transmitting an X-ray to the uncompressed region of interest, an image acquisition system acquiring a plurality of two-dimensional projection images data for a CBCT or CBDT data set with at least one of the projection images acquired in 35 milliseconds or less, and a processor generating a three-dimensional computed tomography image data set resolving voxels with dimensions of 0.4 mm or less in at least two orthogonal directions.

Abstract: Disclosed herein are methods of diagnosing pancreatic cancer in a subject. Also provided are methods of monitoring the efficacy of a therapeutic treatment of pancreatic cancer as well as methods of determining the likelihood that a subject having pancreatic cancer will survive, and methods of determining the suitability of a subject having pancreatic cancer for surgical resection therapy.

Abstract: A method of imaging a patient's uncompressed region of interest using X-ray cone beam computed tomography or cone beam digital tomography comprises the step of introducing an effective amount of a contrast agent to the uncompressed region of interest. A system for imaging a patient's uncompressed region of interest using cone beam computed tomography (CBCT) or cone beam digital tomography (CBDT) comprises an X-ray source transmitting an X-ray to the uncompressed region of interest, an image acquisition system acquiring a plurality of two-dimensional projection images data for a CBCT or CBDT data set with at least one of the projection images acquired in 35 milliseconds or less, and a processor generating a three-dimensional computed tomography image data set resolving voxels with dimensions of 0.4 mm or less in at least two orthogonal directions.

Abstract: A method of imaging a patient's uncompressed region of interest using X-ray cone beam computed tomography or cone beam digital tomography comprises the step of introducing an effective amount of a contrast agent to the uncompressed region of interest. A system for imaging a patient's uncompressed region of interest using cone beam computed tomography (CBCT) or cone beam digital tomography (CBDT) comprises an X-ray source transmitting an X-ray to the uncompressed region of interest, an image acquisition system acquiring a plurality of two-dimensional projection images data for a CBCT or CBDT data set with at least one of the projection images acquired in 35 milliseconds or less, and a processor generating a three-dimensional computed tomography image data set resolving voxels with dimensions of 0.4 mm or less in at least two orthogonal directions.

Abstract: A carton with a new dispenser that can be opened by a pull tab with this dispenser flap being placed in a corner of the top panel of the carton so that it is adjacent to the tops of the small necks of the bottles for easy opening and removal or for opening and reclosing. The dispenser flap is held in position by resistant tear lines but can be easily removed by an attached pull tab that is loosely connected to the top panel.

Abstract: A carton can be placed in a dispensing configuration by separating the carton into dispenser sections. The dispenser sections may be connected by a hinge that allows the sections to stand side-by-side.

Abstract: A method of imaging a patient's uncompressed region of interest using X-ray cone beam computed tomography or cone beam digital tomography comprises the step of introducing an effective amount of a contrast agent to the uncompressed region of interest. A system for imaging a patient's uncompressed region of interest using cone beam computed tomography (CBCT) or cone beam digital tomography (CBDT) comprises an X-ray source transmitting an X-ray to the uncompressed region of interest, an image acquisition system acquiring a plurality of two-dimensional projection images data for a CBCT or CBDT data set with at least one of the projection images acquired in 35 milliseconds or less, and a processor generating a three-dimensional computed tomography image data set resolving voxels with dimensions of 0.4 mm or less in at least two orthogonal directions.

Abstract: The present invention provides novel genes and proteins for diagnosing ovarian cancer and/or a likelihood for survival, or recurrence of disease, wherein the expresson of the genes and proteins is up-regulated or down-regulated or associated with the occurrence or recurrence of a specific cancer sub-type. The ovarian cancer-associated genes and proteins of the invention are specifically exemplified by the genes and proteins set forth in Tables 1 to 5 and the Sequence Listing.

Abstract: The present invention applies classical survival analysis to genome-wide gene expression profiles of prostate cancers and preoperative prostate-specific antigen levels from prostate cancer patient, to identify prognostic markers of disease relapse that provide additional predictive value relative to prostate-specific antigen concentration. The present invention provides a method of determining prognosis of prostate cancer and predicting prostate cancer outcome of a patient. The method comprises the steps of first establishing the threshold value of at least one prognostic gene of prostate cancer. Then, the amount of the prognostic gene from a prostate tissue of a prostate cancer patient is determined. The amount of the prognostic gene present in that patient is compared with the established threshold value of the prognostic gene, whereby the prognostic outcome of the patient is determined.